JPRN-C000000302已完成2 期
Phase II Clinical Trial to test efficacy and safety of relapsed APL (JALSG APL205R study) - Phase II Clinical Trial for relapsed APL (JALSG APL205R study)
Japan adult leukemia study group ( JALSG)0 个研究点目标入组 20 人开始时间: 2005年12月30日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Uncontrolled active infection 2. Past history of myocardial infarction or cardiac failure 3. Past history of renal failure 4. Uncontrolled diabetes mellitus 5. Liver cirrhosis 6. Abnormal reaction to ATO and AraC 7. Another severe and/or life threatening disease 8. Pregnant and/or lactating woman 9. Relapse after stem cell transplantation 10.Impossible to process this protocol
研究者
相似试验
已完成
不适用
Phase II Clinical Trial to Test Efficacy and Safety of Autologous Peripheral Stem Cell Transplantation for Multiple Myeloma (C-SHOT 0401)multiple myelomaJPRN-C000000178Center for Supporting Hematology-Oncology Trials (C-SHOT)60
进行中（未招募）
1 期
Clinical trial - phase II - to test safety and efficay of Etravirine's treatment in FriedreichFriedreich's ataxiaMedDRA version: 20.0Level: PTClassification code 10017374Term: Friedreich's ataxiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2019-002618-38-ITASSOCIAZIONE LA NOSTRA FAMIGLIA - SEZIONE SCIENTIFICA I.R.C.C.S. E.MEDEA35
进行中（未招募）
1 期
Trastuzumab and AUY922 in HER2-aberrant NSCLCAdvanced non-smallcell lung cancer with HER2 - overexpression or - amplification or - mutationMedDRA version: 17.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-005655-13-DEniversity of Cologne29
进行中（未招募）
1 期
A phase II trial to evaluate safety and efficacy of adding durvalumab (MEDI4736) to standard neoadjuvant radiochemotherapy and of adjuvant durvalumab +/- tremelimumab in locally advanced esophageal adenocarcinoma and to evaluate biomarkers predictive for response to immune checkpoint inhibitiolocally advanced esophageal adenocarcinomaMedDRA version: 20.0Level: LLTClassification code 10001173Term: Adenocarcinoma of esophagusSystem Organ Class: 100000004864EUCTR2018-003048-22-DEniversität zu Köln56
尚未招募
2 期
A phase II trial to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small cell lung cancer (NSCLC) with HER2 - overexpression or -amplification or - mutation.HER2-overexpression or -amplification or -mutationC34Malignant neoplasm of bronchus and lungDRKS00003301niversität Köln29